MG
INBX icon

Michael Gelband’s Inhibrx INBX Stock Holding History

Michael Gelband’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$532K Sell
5,612
-25,368
-82% -$2.54M ﹤0.01% 1228
2026
Q1 		$2.08M Buy
+30,980
New +$2.3M 0.02% 769

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's INBX Position: Q2 2026 in Review

Michael Gelband reduced its Inhibrx (INBX) stake by 82% in Q2 2026, selling an estimated $2.54M and leaving 5,612 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #1228.

Michael Gelband first reported a position in INBX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.08M in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Michael Gelband held 5,612 shares of Inhibrx worth $532K as of Q2 2026.
  • Michael Gelband sold 25,368 Inhibrx shares in Q2 2026, an estimated $2.54M.
  • Inhibrx made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1228 holding.
  • Michael Gelband first reported a position in Inhibrx in Q1 2026 and has held it in 2 quarters since.
  • Michael Gelband's Inhibrx position peaked at $2.08M in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.